Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 6, Pages 1207
Publisher
MDPI AG
Online
2021-03-15
DOI
10.3390/jcm10061207
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
- (2020) David A. Bond et al. BLOOD
- Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
- (2020) Rory McCulloch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy of venetoclax in high risk relapsed mantle cell lymphoma ( MCL ) ‐ outcomes and mutation profile from venetoclax resistant MCL patients
- (2020) Shuangtao Zhao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
- (2020) Yuqin Song et al. CLINICAL CANCER RESEARCH
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes
- (2020) Ferran Nadeu et al. BLOOD
- Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma
- (2020) Daniel Guy et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
- (2020) Jordan Gauthier et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma
- (2020) Jia Ruan HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
- (2020) Caron A. Jacobson et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
- (2020) Carlo Visco et al. LEUKEMIA
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists
- (2020) Kristin L. Koenig et al. Blood Advances
- Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
- (2020) Steven Le Gouill et al. BLOOD
- A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
- (2019) Peter Martin et al. BLOOD
- Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse
- (2019) Anita Kumar et al. Blood Cancer Journal
- UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111)
- (2019) C.S. Tam et al. HEMATOLOGICAL ONCOLOGY
- Treatment of Relapsed/Refractory Non Hodgkin Lymphoma Patients with Venetoclax Therapy: A Single-Center Evaluation of off-label use
- (2019) Mitchell E. Hughes et al. Clinical Lymphoma Myeloma & Leukemia
- KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
- (2019) Simone Ferrero et al. HAEMATOLOGICA
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
- (2019) Michael Wang et al. LEUKEMIA
- Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
- (2019) Young‐Woo Jeon et al. Cancer Medicine
- Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2018) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
- (2018) Mats Jerkeman et al. Lancet Haematology
- Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
- (2018) Toby A. Eyre et al. HAEMATOLOGICA
- Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
- (2018) Martin Dreyling et al. BLOOD
- Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death
- (2018) Carlo Visco et al. BRITISH JOURNAL OF HAEMATOLOGY
- Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterations
- (2018) Richard J. Lin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis
- (2018) Simon Rule et al. HAEMATOLOGICA
- Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma
- (2018) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
- (2017) Steven Le Gouill et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- Postibrutinib outcomes in patients with mantle cell lymphoma
- (2016) P. Martin et al. BLOOD
- Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma
- (2016) Antònia Obrador-Hevia et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network
- (2016) Eva Hoster et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
- (2016) Olivier Hermine et al. LANCET
- Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
- (2016) Mathias Rummel et al. LANCET ONCOLOGY
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
- (2016) Michael L Wang et al. LANCET ONCOLOGY
- Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
- (2016) Marek Trněný et al. LANCET ONCOLOGY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
- (2015) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
- (2015) M.-H. Delfau-Larue et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network
- (2014) Eva Hoster et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)
- (2014) Vicki A. Morrison et al. LEUKEMIA & LYMPHOMA
- Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
- (2013) P. L. Zinzani et al. ANNALS OF ONCOLOGY
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation
- (2013) Carlo Visco et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
- (2013) David Salek et al. LEUKEMIA & LYMPHOMA
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
- (2011) R. Kridel et al. BLOOD
- Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma
- (2011) W. Lamm et al. HAEMATOLOGICA
- Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation
- (2011) Lihua E. Budde et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
- (2009) C. H. Geisler et al. BLOOD
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
- (2008) K. Sue Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started